Is QURE a good stock to buy?
We came across a bullish thesis on uniQure N.V. on r/stocks by AntoniaFauci
In this article, we will summarize the bulls’ thesis on QURE. uniQure N.V.’s share was trading at $20.68 as of May 4th. QURE’s trailing and forward P/E were 2.68 and 5.04 respectively according to Yahoo Finance. Pressmaster/ uniQure N.V. is a rare disease-focused biotech company developing gene therapies, highlighted by a breakthrough treatment for Huntington’s Disease, a fatal and rapidly degenerative condition with no prior effective therapy.
The company demonstrated compelling clinical results, including a 75% reduction in disease progression, significantly extending patient life expectancy and improving quality of life, with anecdotal evidence of delayed disability and even return to work. 15 AI Stocks That Are Quietly Making Investors Rich Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential Following these results, the stock surged sharply, reflecting the magnitude of the medical advancement. However, this trajectory reversed after Marty Makary, the FDA chair, unexpectedly suspended the approval process without clear justification, creating significant uncertainty. Subsequent public remarks from Makary criticizing gene therapy methodologies, including controversial views on trial design and placebo use in invasive procedures, were widely interpreted as targeting uniQure, further eroding confidence despite unclear alignment with the company’s actual practices.